Affiliation:
1. Bristol Laboratories, Division of Bristol-Myers Co., Syracuse, New York 13201
Abstract
In a single-blinded study, two groups of 10 healthy subjects were given cephapirin or cephalothin by continuous intravenous infusion for 5 days, 0.5 g every 6 hr for the first day and then 1.0 g every 6 hr for 4 days. Eight of the cephalothin subjects and two of the cephapirin subjects developed phlebitis. Phlebitis was more severe in the cephalothin group and developed more rapidly, necessitating vein changes six times more often than in the cephapirin group. The less irritating properties of cephapirin demonstrated in this study indicate it may be the more useful cephalosporin analogue for intravenous therapy.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference9 articles.
1. Cephapirin: in vitro antibacterial spectrum;Axelrod J.;Appl. Microbiol.,1971
2. Clinical and in vitro evaluation of cephapirin: a new parenteral cephalosporin;Bodner S. J.;Amer. J. Med. Sci.,1972
3. Clinical and in vitro evaluation of cephapirin, a new cephalosporin antibiotic;Bran J. L.;Antimicrob. Ag. Chemother.,1972
4. Laboratory studies with a new cephalosporanic acid derivative;Chisholm D. R.;Antimicrob. Ag. Chemother.,1970
5. Cephapirin: clinical, pharmacological and microbiological studies;Jameson S.;Del. Med. J.,1971
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献